Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
By activating three distinct vasopressin receptor isoforms called V1a-R, V1b-R (V3-R) and V2-R, vasopressin (VP) mediates a wide number of biological effects in mammals and may be involved in several pathological states. Up to now only specific V1a and V2 receptor agonists and antagonists have been successfully designed. The role of the V1b-R still remains partially unknown, due to the lack of selective V1b-R ligands and orally-active molecules, which are crucial tools for investigating the central and peripheral functions or pathological disorders associated with this receptor. In this review, we report the biological and pharmacological properties of the first two specific V1b-R ligands: d[Cha4] AVP, a high affinity V1b-R agonist and SSR149415, a potent orally-active V1b-R antagonist with good selectivity with respect to other VP/OT receptor isoforms and able to control ACTH secretion in vitro and in vivo. Indeed, these molecules constitute invaluable tools for exploring the central and peripheral roles of VP mediated via V1b receptors. Interestingly, SSR149415 displays potent anxiolytic and antidepressant-like activities, indicating that this new class of drugs has a promising therapeutical potential in the treatment of stress-related disorders, anxiety and depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965 · cited 7×
“VP exerts a dual effect as a direct ACTH secretagogue and also potentiates the stimulatory effect of corticotropin releasing factor (CRF) (Gillies et al., 1982).”
BackgroundInfluentialRaadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · cited 2×
“Neither did the drug modify sleep patterns following EEG analysis nor impair learning in the Morris water maze up to 30 mg/kg in mice or rats (Griebel et al., 2002).”
BackgroundSelf-citationVasopressin V1b receptor knockout reduces aggressive behavior in male mice
Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397
Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375 · cited 1×
“Importantly, VP also plays a major role during adaptation to stress (Aguilera and Rabadan-Diehl, 2000).”
BackgroundVaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308
Molecular biology of vasopressin receptors
LOLAIT, S. J., O'CARROLL, A., & BROWNSTEIN, M. J. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44688.x · Cited by 87
Regulation of Pituitary Vasopressin V1b Receptor mRNA during Stress in the Rat
Rabadan‐Diehl, C., Lolait, S. J., & Aguilera, G. (1995) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1995.tb00734.x · Cited by 86 · cited 2×
“The expression of VP in the parvocellular neurons of the paraventricular nucleus and its secretion into the portal circulation increases under chronic stress conditions (Rabadan-Diehl et al., 1995).”
Background
Cited by
Vasopressin: Behavioral roles of an “original” neuropeptide
Caldwell, H. K., Lee, H.-J., Macbeth, A. H., & Young, W. S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.007 · Cited by 504
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
“The compound SSR149415 is an orally available highly selective nonpeptide V1B receptor antagonist (Serradeil-Le Gal et al. 2002) that was tested in a number of animal models of anxietyand antidepressant-like behavior (Serradeil-Le Gal et al. 2003).”
BackgroundVasopressin V1a and V1b Receptors: From Molecules to Physiological Systems
Koshimizu, T.-A., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H., & Tanoue, A. (2012) · Physiological Reviews · doi:10.1152/physrev.00035.2011 · Cited by 407
The Vasopressin System: Physiology and Clinical Strategies
Treschan, T. A., Peters, J., & Warltier, D. C. (2006) · Anesthesiology · doi:10.1097/00000542-200609000-00026 · Cited by 316
Zhou, Y., Leri, F., Cummins, E., Hoeschele, M., & Kreek, M. J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301419 · Cited by 89
Metadata
- Authors
- Claudine, S.-L. G., Sylvain, D., Gabrielle, B., Maurice, M., Jacques, S., Rolf, G., Guy, G., & Gilles, G.
- Venue
- Stress
- Publisher
- Informa UK Limited
- Published
- 2003-01
- Volume
- 6
- Issue
- 3
- Pages
- 199-206
- ISSN
- 1025-3890 (ISSN-L)
- 1607-8888
- OpenAlex
- W2093651141
- Cited by
- 92
- References
- 11
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals. https://app.cochat.ai/papers/10.1080/1025389032000114524
- The paper
- Claudine, S.-L. G., Sylvain, D., Gabrielle, B., Maurice, M., Jacques, S., Rolf, G., Guy, G., & Gilles, G. (2003). Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals. Stress. https://doi.org/10.1080/1025389032000114524
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.